{"id":744267,"date":"2023-03-31T08:18:19","date_gmt":"2023-03-31T12:18:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/"},"modified":"2023-03-31T08:18:19","modified_gmt":"2023-03-31T12:18:19","slug":"ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/","title":{"rendered":"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MALVERN, Pa., March  31, 2023  (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company\u2019s Chief Scientific Officer, Arun Upadhyay, PhD, will present at the World Vaccine Congress being held April 3 \u2013 6 in Washington D.C.<\/p>\n<p>\u201cCurrent COVID-19 vaccines are limited by a lack of durability and inability to stop infection and transmission,\u201d said Dr. Upadhyay. \u201cInhaled vaccines have the potential to generate rapid mucosal immunity in respiratory pathways, limiting infection and transmission. I look forward to discussing Ocugen\u2019s inhaled vaccine technology\u2014to address COVID-19 and flu\u2014during the World Vaccine Congress.\u201d<\/p>\n<p>Ocugen is currently developing a novel mucosal vaccine platform that includes OCU500, a bivalent COVID-19 inhaled vaccine; OCU510, a seasonal quadrivalent flu inhaled vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 inhaled vaccine. The OCU500 series grants Ocugen a distinct product candidate profile status that could significantly impact major global health obstacles and maximize the Company\u2019s opportunity to serve broader patient markets. For the 2022 to 2023 flu season, in the United States alone, more than 50% of the population above six months of age received a seasonal flu shot, representing a market size of more than 170 million doses.<\/p>\n<p>Details on Dr. Upadhyay\u2019s participation are as follows:<\/p>\n<p>\n        <strong>Presentation<\/strong><br \/>\n        <strong>Title:<\/strong> \u201cA next generation inhalation-based mucosal vaccine for COVID-19 and Flu: Potential approach to reduce infection and transmission\u201d <br \/><strong>Date: <\/strong>Wednesday, April 5, 2023<br \/><strong>Time:<\/strong> 5:40 p.m. ET <br \/><strong>Location:<\/strong> Walter E. Washington Convention Center, Washington D.C. \u2013 Level 2, Room 203AB<\/p>\n<p>\n        <strong>Roundtable Discussion<\/strong><br \/>\n        <strong>Title: <\/strong>\u201cGoing beyond existing limitations \u2013 Why mucosal vaccines are essential for respiratory diseases\u201d<br \/><strong>Date: <\/strong>Tuesday, April 4, 2023<br \/><strong>Time: <\/strong>11:40 \u2013 12:20 p.m. ET (rotation 1); 12:30 \u2013 1:10 p.m. ET (rotation 2) <br \/><strong>Location: <\/strong>Walter E. Washington Convention Center, Washington D.C. \u2013 Room 203B<\/p>\n<p>\n        <strong>About Ocugen, Inc<\/strong>.<br \/>Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient\u2019s lives through courageous innovation\u2014forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HdFwBCvkRMW3hGTg-dr9NffuiJPoc87u2EwBdSq7iznEHLxWmjLfTM9t925bKJEgq_9vAo8rLMknX0Rvgx_ncwwjro2ODTIDJHdMAnykYPSrtjF-EsE_z7gFE43XLS__YEyf0rq3wbLxj7HInYO-RijoWFMaDb-4hPL0NKl3GYEk9wyYB58nzlIOK3sCxvUWZBLdrnF8MNn2s7dExN34QPJvzUbt78RQdsVRzRQXIzw=\" rel=\"nofollow noopener\" target=\"_blank\">www.ocugen.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9FPUmieUF8dbtl7lK5XUTE6MQFtb0vt_Exkz1Hil0VHA4EdSAWniZO2vts82aDTdUTQMD-nI0OkjDnAyStGFQbGjSb9nGrDyws1Fkg5JPTutFoe35vcFxOVHEvbTugAip3IuEEFQIW8pldb9AUc0BzyCm7PpJ6irsua27f-V5RqR_hKWC8bKi5COYarheYHCRrxQt7etWUhyXl4pA2aw-4C8DjuJ5-qmF9SkDAEknucEPlRUh62Rcmw_1sreD1qOQZf7OQZPOCmunFt530sO9wNAEaukuMT9bEA3wFnKxjU=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kgTbOAPSGmk2TDhOsqYPrUmStq1zA4Yl_0nPDJfLyXrq8Sit_aDhlymeIQ20nQvPbFehg5XfczluwhOQYsq39Tcp_dAx2LhP76A6C8GdKvhIiwz_Jk9me79U_JuotoiW4VPictO9gtm_OmL1yTJowyleU_k_TwQWUlqWJvcGLcZweqJC_F8Lzr1ZvWXy93SpbOCPhuTapDwQJ68xaY5ZCG21AAGnq9NgZrBfXlx7-j5AZtE0wDcCgpk8FdcXbZng\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn.<\/a><\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled \u201cRisk Factors\u201d in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.<\/em>\n      <\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>\n        <strong>Tiffany Hamilton<\/strong><br \/>\n        <br \/>\n        <strong>Head of Communications<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yNYCq3LR7HIDW1mFx84PqjcB-SB1SwppXyQgaW-UEvvZABJf6srFgcnQsknTvXJf3165PRgfrgJMDaN5FWR0CA==\" rel=\"nofollow noopener\" target=\"_blank\">IR@ocugen.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDc5NjU3ZjEtMTYyOS00ODIwLTkxNzMtZWVjNjJlZWFhMmQ3LTExOTYwNzM=\/tiny\/Ocugen.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company\u2019s Chief Scientific Officer, Arun Upadhyay, PhD, will present at the World Vaccine Congress being held April 3 \u2013 6 in Washington D.C. \u201cCurrent COVID-19 vaccines are limited by a lack of durability and inability to stop infection and transmission,\u201d said Dr. Upadhyay. \u201cInhaled vaccines have the potential to generate rapid mucosal immunity in respiratory pathways, limiting infection and transmission. I look forward to discussing Ocugen\u2019s inhaled vaccine technology\u2014to address COVID-19 and flu\u2014during the World Vaccine Congress.\u201d Ocugen is currently developing a novel &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-744267","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company\u2019s Chief Scientific Officer, Arun Upadhyay, PhD, will present at the World Vaccine Congress being held April 3 \u2013 6 in Washington D.C. \u201cCurrent COVID-19 vaccines are limited by a lack of durability and inability to stop infection and transmission,\u201d said Dr. Upadhyay. \u201cInhaled vaccines have the potential to generate rapid mucosal immunity in respiratory pathways, limiting infection and transmission. I look forward to discussing Ocugen\u2019s inhaled vaccine technology\u2014to address COVID-19 and flu\u2014during the World Vaccine Congress.\u201d Ocugen is currently developing a novel &hellip; Continue reading &quot;Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-31T12:18:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress\",\"datePublished\":\"2023-03-31T12:18:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/\"},\"wordCount\":621,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/\",\"name\":\"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=\",\"datePublished\":\"2023-03-31T12:18:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/","og_locale":"en_US","og_type":"article","og_title":"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress - Market Newsdesk","og_description":"MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company\u2019s Chief Scientific Officer, Arun Upadhyay, PhD, will present at the World Vaccine Congress being held April 3 \u2013 6 in Washington D.C. \u201cCurrent COVID-19 vaccines are limited by a lack of durability and inability to stop infection and transmission,\u201d said Dr. Upadhyay. \u201cInhaled vaccines have the potential to generate rapid mucosal immunity in respiratory pathways, limiting infection and transmission. I look forward to discussing Ocugen\u2019s inhaled vaccine technology\u2014to address COVID-19 and flu\u2014during the World Vaccine Congress.\u201d Ocugen is currently developing a novel &hellip; Continue reading \"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-31T12:18:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress","datePublished":"2023-03-31T12:18:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/"},"wordCount":621,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/","name":"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=","datePublished":"2023-03-31T12:18:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5OTQ0MSM1NTAyNTY4IzIxODQ1MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-chief-scientific-officer-to-present-at-2023-world-vaccine-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=744267"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/744267\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=744267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=744267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=744267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}